Transgenic expression of cyclooxygenase-2 in hepatocytes accelerates endotoxin-induced acute liver failure

Journal of Immunology

Volumn 181, Issue 11, 2009, Pages 8027-8035

  Han, Chang ^a   Li, Guiying ^a,b   Lim, Kyu ^a,c   DeFrances, Marie C ^a   Gandhi, Chandrashekhar R ^a   Wu, Tong ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c Chungnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; CASPASE 3; CASPASE 9; CYCLOOXYGENASE 2; GALACTOSAMINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTAGLANDIN E RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CONTROLLED STUDY; DISEASE EXACERBATION; GENE EXPRESSION; GENE TARGETING; INFLAMMATION; LIVER CELL; LIVER FAILURE; LIVER INJURY; MORTALITY; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSGENE; TRANSGENIC MOUSE; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

EID: 71849089004     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.11.8027     Document Type: Article

References (51)

1. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
2. Williams, R. 1996. Classification, etiology, and considerations of outcome in acute liver failure. Semin. Liver Dis. 16: 343-348. (Pubitemid 27074776)
3. Ostapowicz, G., and W. M. Lee. 2000. Acute hepatic failure: a Western perspective. J Gastroenterol. Hepatol. 15: 480-488. (Pubitemid 30327048)
4. Kang, Y. J., B. A. Wingerd, T. Arakawa, and W. L. Smith. 2006. Cyclooxygenase-2 gene transcription in a macrophage model of inflammation. J. Immunol. 177: 8111-8122. (Pubitemid 44846330)
5. Callejas, N. A., L. Bosca, C. S. Williams, B. R. Du, and P. Martin-Sanz. 2000. Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins. Gastroenterology 119: 493-501. (Pubitemid 30621999)
6. Funk, C. D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
7. Narumiya, S., and G. A. FitzGerald. 2001. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108: 25-30. (Pubitemid 32634917)
8. Breyer, R. M., C. K. Bagdassarian, S. A. Myers, and M. D. Breyer. 2001. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41: 661-690.
9. Ivanov, A. I., and A. A. Romanovsky. 2004. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Front Biosci. 9: 1977-1993.
10. Oka, T. 2004. Prostaglandin E2 as a mediator of fever: the role of prostaglandin E (EP) receptors. Front Biosci. 9: 3046-3057.
11. Jirillo, E., D. Caccavo, T. Magrone, E. Piccigallo, L. Amati, A. Lembo, C. Kalis, and M. Gumenscheimer. 2002. The role of the liver in the response to LPS: experimental and clinical findings. J. Endotoxin Res. 8: 319-327. (Pubitemid 35460666)
12. Han, D. W. 2002. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J. Gastroenterol. 8: 961-965.
13. Su, G. L. 2002. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. 283: G256-G265. (Pubitemid 34791290)
14. Bell, A., Q. Chen, M. C. DeFrances, G. K. Michalopoulos, and R. Zarnegar. 1999. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice. Oncogene 18: 887-895. (Pubitemid 29086265)
15. Wang, X., M. C. DeFrances, Y. Dai, P. Pediaditakis, C. Johnson, A. Bell, G. K. Michalopoulos, and R. Zarnegar. 2002. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell 9: 411-421. (Pubitemid 34195565)
16. 2 and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 36: 363-373.
17. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76: 5939-5943. (Pubitemid 10216692)
18. Leist, M., F. Gantner, I. Bohlinger, G. Tiegs, P. G. Germann, and A. Wendel. 1995. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol. 146: 1220-1234.
19. Bohlinger, I., M. Leist, F. Gantner, S. Angermuller, G. Tiegs, and A. Wendel. 1996. DNA fragmentation in mouse organs during endotoxic shock. Am. J. Pathol. 149: 1381-1393. (Pubitemid 26337255)
20. Deutschman, C. S., B. A. Haber, K. Andrejko, D. E. Cressman, R. Harrison, E. Elenko, and R. Taub. 1996. Increased expression of cytokine-induced neutrophil chemoattractant in septic rat liver. Am. J. Physiol. 271: R593-R600. (Pubitemid 126757651)
21. Kosai, K., K. Matsumoto, H. Funakoshi, and T. Nakamura. 1999. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology 30: 151-159. (Pubitemid 29300581)
22. Jiang, W., R. Sun, H. Wei, and Z. Tian. 2005. Toll-like receptor 3 ligand attenuates LPS-induced liver injury by down-regulation of Toll-like receptor 4 expression on macrophages. Proc. Natl. Acad. Sci. USA 102: 17077-17082. (Pubitemid 41692686)
23. Masaki, T., S. Chiba, H. Tatsukawa, H. Noguchi, T. Kakuma, M. Endo, M. Seike, T. Watanabe, and H. Yoshimatsu. 2005. The role of histamine H1 receptor and H2 receptor in LPS-induced liver injury. FASEB J. 19: 1245-1252.
24. Jaeschke, H., and J. J. Lemasters. 2003. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125: 1246-1257. (Pubitemid 37193469)
25. Wang, H., D. X. Xu, J. W. Lv, H. Ning, and W. Wei. 2007. Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. Toxicology 237: 49-57. (Pubitemid 47031404)
26. Harstad, E. B., and C. D. Klaassen. 2002. Tumor necrosis factor-α-null mice are not resistant to cadmium chloride-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 179: 155-162. (Pubitemid 34275958)
27. Wang, Y. M., G. H. Feng, F. Huang, Y. Li, and G. Z. Zhao. 2003. Tumor necrosis factor-α, caspase-3 expression and hepatocyte apoptosis in fulminanting hepatic failure. Zhonghua Nei Ke Za Zhi. 42: 566-570.
28. Sass, G., M. C. Soares, K. Yamashita, S. Seyfried, W. H. Zimmermann, T. Eschenhagen, E. Kaczmarek, T. Ritter, H. D. Volk, and G. Tiegs. 2003. Heme oxygenase-1 and its reaction product, carbon monoxide, prevent inflammation-related apoptotic liver damage in mice. Hepatology 38: 909-918. (Pubitemid 37221674)
29. Hoglen, N. C., L. S. Chen, C. D. Fisher, B. P. Hirakawa, T. Groessl, and P. C. Contreras. 2004. Characterization of IDN-6556 (3-(2-(2-tert- butylphenylaminooxalyl)-amino)-propionylamino)-4-oxo-5-(2,3,5, 6-tetrafluorophenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J. Pharmacol. Exp. Ther. 309: 634-640.
30. Qiu, Z., A. H. Kwon, K. Tsuji, Y. Kamiyama, T. Okumura, and Y. Hirao. 2006. Fibronectin prevents D-galactosamine/lipopolysaccharide-induced lethal hepatic failure in mice. Shock 25: 80-87. (Pubitemid 43755991)
31. Luster, M. I., D. R. Germolec, T. Yoshida, F. Kayama, and M. Thompson. 1994. Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology 19: 480-488. (Pubitemid 24046795)
32. Chensue, S. W., P. D. Terebuh, D. G. Remick, W. E. Scales, and S. L. Kunkel. 1991. In vivo biologic and immunohistochemical analysis of interleukin-1α, β and tumor necrosis factor during experimental endotoxemia: kinetics, Kupffer cell expression, and glucocorticoid effects. Am. J. Pathol. 138: 395-402.
33. Ip, Y. T., and R. J. Davis. 1998. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr. Opin. Cell Biol. 10: 205-219. (Pubitemid 28174763)
34. Trautwein, C., T. Rakemann, D. A. Brenner, K. Streetz, L. Licato, M. P. Manns, and G. Tiegs. 1998. Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice. Gastroenterology 114: 1035-1045. (Pubitemid 28217571)
35. Bendinelli, P., R. Piccoletti, P. Maroni, and A. Bernelli-Zazzera. 1996. The MAP kinase cascades are activated during post-ischemic liver reperfusion. FEBS Lett. 398: 193-197. (Pubitemid 26414308)
36. Schattenberg, J. M., R. Singh, Y. Wang, J. H. Lefkowitch, R. M. Rigoli, P. E. Scherer, and M. J. Czaja. 2006. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 43: 163-172.
37. Wang, Y., R. Singh, J. H. Lefkowitch, R. M. Rigoli, and M. J. Czaja. 2006. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J. Biol. Chem. 281: 15258-15267. (Pubitemid 43855115)
38. Chang, L., H. Kamata, G. Solinas, J. L. Luo, S. Maeda, K. Venuprasad, Y. C. Liu, and M. Karin. 2006. The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIPL turnover. Cell 124: 601-613. (Pubitemid 43199444)
39. Maeda, S., L. Chang, Z. W. Li, J. L. Luo, H. Leffert, and M. Karin. 2003. IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα. Immunity 19: 725-737. (Pubitemid 37490797)
40. 2 (EP(1)) receptor agonist-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes: the involvement of TGF-α. Endocrinology 142: 4428-4440.
41. 2 receptor EP(1) transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell Physiol. 207: 261-270.
42. Lehmann, V., M. A. Freudenberg, and C. Galanos. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine- treated mice. J. Exp. Med. 165: 657-663. (Pubitemid 17059444)
43. Sass, G., S. Heinlein, A. Agli, R. Bang, J. Schumann, and G. Tiegs. 2002. Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19: 115-120. (Pubitemid 35216191)
44. Ganey, P. E., Y. W. Barton, S. Kinser, R. A. Sneed, C. C. Barton, and R. A. Roth. 2001. Involvement of cyclooxygenase-2 in the potentiation of allyl alcohol-induced liver injury by bacterial lipopolysaccharide. Toxicol. Appl. Pharmacol. 174: 113-121.
45. Kondo, M., H. Yamamoto, H. Nagano, J. Okami, Y. Ito, J. Shimizu, H. Eguchi, A. Miyamoto, K. Dono, K. Umeshita, N. Matsuura, et al. 1999. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin. Cancer Res. 5: 4005-4012. (Pubitemid 30013777)
46. Morinaga, S., Y. Yamamoto, Y. Noguchi, T. Imada, Y. Rino, M. Akaike, Y. Sugimasa, S. Takemiya, Y. Kameda, and Y. Takanashi. 2002. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J. Gastroenterol. Hepatol. 17: 1110-1116. (Pubitemid 35013968)
47. 2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol. Res. 23: 185-195.
48. Mohammed, N. A., S. A. Abd El-Aleem, H. A. El-Hafiz, and R. F. McMahon. 2004. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol. 57: 350-354. (Pubitemid 38446249)
49. Fosslien, E. 2005. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann. Clin. Lab. Sci. 35: 347-385. (Pubitemid 41581673)
50. Grosser, T., S. Fries, and G. A. FitzGerald. 2006. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116: 4-15. (Pubitemid 43121782)
51. Warner, T. D., and J. A. Mitchell. 2004. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 18: 790-804.